Oral Pharmacotherapy for Male Sexual Dysfunction (eBook)

A Guide to Clinical Management

Gregory A. Broderick (Herausgeber)

eBook Download: PDF

2007 | 2005
464 Seiten
Humana Press (Verlag)
978-1-59259-871-7 (ISBN)

Infos

For the generation that reached sexual maturity in the 1960s, the 'pill' became synonymous with sexual freedom and started a sexual revolution. For women it meant freedom from the fear of pregnancy, and for men enhanced sexual opportunity. The new era of the pill has nothing to do with fertility, but everything to do with sex. The first orally effective prescr- tion drug for treating erectile dysfunction (ED) was marketed in 1998. ® Sildenafil (Viagra ) has rejuvenated the aging male veterans of the sexual revolution, forever changed the science of sexual medicine, and tra- formed society's perspective on aging and sex. This class of drugs, known as oral phosphodiesterase inhibitors (PDE-type 5), is highly effective in the treatment of ED. Since its introduction there has been a much greater awa- ness of ED, its comorbidities, and its effects on the quality of life. In 1997, while preparing to address the Endocrine Society on the occasion of the 92nd American Urological Association meeting, I first looked at the p- clinical studies of sildenafil. I thought 'this will change everything' and it clearly has-changing practice patterns in sexual medicine, and the at- tudes of patients, potential patients, and their partners. Two new PDE-type ® ® 5 inhibitors, tadalafil (Cialis ) and vardenafil (Levitra ), were first approved by the European Committee for Proprietary Medicinal Products and subsequently by the Food and Drug Administration in 2003 and 2004.

---

For the generation that reached sexual maturity in the 1960s, the "e;pill"e; became synonymous with sexual freedom and started a sexual revolution. For women it meant freedom from the fear of pregnancy, and for men enhanced sexual opportunity. The new era of the pill has nothing to do with fertility, but everything to do with sex. The first orally effective prescr- tion drug for treating erectile dysfunction (ED) was marketed in 1998. (R) Sildenafil (Viagra ) has rejuvenated the aging male veterans of the sexual revolution, forever changed the science of sexual medicine, and tra- formed society's perspective on aging and sex. This class of drugs, known as oral phosphodiesterase inhibitors (PDE-type 5), is highly effective in the treatment of ED. Since its introduction there has been a much greater awa- ness of ED, its comorbidities, and its effects on the quality of life. In 1997, while preparing to address the Endocrine Society on the occasion of the 92nd American Urological Association meeting, I first looked at the p- clinical studies of sildenafil. I thought "e;this will change everything"e; and it clearly has-changing practice patterns in sexual medicine, and the at- tudes of patients, potential patients, and their partners. Two new PDE-type (R) (R) 5 inhibitors, tadalafil (Cialis ) and vardenafil (Levitra ), were first approved by the European Committee for Proprietary Medicinal Products and subsequently by the Food and Drug Administration in 2003 and 2004.

Inhalt

Physiology and Pharmacology of Erectile Dysfunction
Rafael Carrion, Derek Bochinski, Nadeem Rahman, and Tom F. Lue

Epidemiology of Erectile Dysfunction
Jonathan D. Schiff and John P. Mulhall

Pharmacology of Phosphodiesterase Inhibitors
Erwin Bischoff

Sildenafil Citrate, the Classical PDE5 Inhibitor: A Five-Year Review of its Efficacy and Safety in the Arena of Erectile Dysfunction
Harin Padma-Nathan

Tadalafil: Clinical Trials Experience
Culley C. Carson, III

Vardenafil: Clinical Trials Experience
Ajay Nehra

Erectile Dysfunction Assessment and Management in Primary Care Practice
Louis Kuritzky and Martin Miner

When to Refer the Patient With Erectile Dysfunction to a Specialist
Ira D. Sharlip

Erectile Dysfunction: Assessing Risk and Managing the Cardiac Patient
Thorsten Reffelmann and Robert A. Kloner

Is Diabetic Erectile Dysfunction More Difficult to Treat?
Pierre Theuma and Vivian A. Fonseca

Depression and Antidepressant-Associated Erectile Dysfunction
Raymond C. Rosen

Intracavernous, Transurethral, and Topical Therapies for Erectile Dysfunction in the Era of Oral Pharmacotherapy: Salvaging First-Line Therapy Failures With Combination Therapies
Hans-Martin A. Fritsche, Mustafa F. Usta, and Wayne J. G. Hellstrom

Androgen Deficiency of the Aging Male: Enhancing Erectile Response to Oral Pharmacotherapy
Alvaro Morales and Jeremy P. W. Heaton

Central Activation of Erection and Clinical Experience
Jeremy P. W. Heaton, Alvaro Morales, and Michael A. Adams

Sustaining the Cure: Oral Pharmacotherapy Failures Salvag With Vacuum Devices and Penile Implants
Ronald W. Lewis

Prevention and Treatment of Erectile Dysfunction Utilizing Lifestyle Changes and Dietary Supplements: What Works and What is Worthless?
Mark A. Moyad

Pharmacological Strategies in the Management of Rapid Ejaculation
Chris G. McMahon

Sexual Dysfunction After Radical Prostatectomy and the Use of PDE-5 Inhibitors
Andrew McCullough

Female Sexual Dysfunction: Is There a Magic Pill?
Ridwan Shabsigh, Anne R. Davis, Aristotelis G. Anastasiadis, Nawras Makhsida, and Grace Yan

Index

Produkt-Details

• Erscheint lt. Verlag: 6.11.2007
• Reihe/Serie: Current Clinical Urology
• Reihe/Serie: Current Clinical Urology
• Zusatzinfo: 464 p. 100 illus.
• Verlagsort: Totowa
• Sprache: englisch
• Themenwelt: Medizin / Pharmazie ► Medizinische Fachgebiete ► Urologie
• Themenwelt: Studium ► 1. Studienabschnitt (Vorklinik) ► Histologie / Embryologie
• Schlagworte: Assessment • Internist • patients • Primary Care • quality • Safety
• ISBN-10: 1-59259-871-4 / 1592598714
• ISBN-13: 978-1-59259-871-7 / 9781592598717